

Ulrike Bacher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1807334/publications.pdf>

Version: 2024-02-01

142
papers

3,111
citations

236925

25
h-index

197818

49
g-index

148
all docs

148
docs citations

148
times ranked

4365
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic relevance of FLT3-TKD mutations in AML: the combination mattersâ€”an analysis of 3082 patients. <i>Blood</i> , 2008, 111, 2527-2537.	1.4	354
2	Implications of NRAS mutations in AML: a study of 2502 patients. <i>Blood</i> , 2006, 107, 3847-3853.	1.4	273
3	Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. <i>Lancet Rheumatology</i> , The, 2021, 3, e789-e797.	3.9	179
4	Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?. <i>Blood</i> , 2012, 120, 4256-4262.	1.4	128
5	Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. <i>Nature Medicine</i> , 2020, 26, 1459-1467.	30.7	122
6	Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. <i>Blood Cancer Journal</i> , 2018, 8, 113.	6.2	90
7	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1796-1803.	2.0	73
8	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
9	Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. <i>Experimental Hematology</i> , 2009, 37, 135-142.	0.4	66
10	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
11	Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. <i>Blood</i> , 2012, 119, 4719-4722.	1.4	62
12	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	4.1	61
13	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamideâ€”Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868.	2.0	58
14	Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. <i>Annals of Hematology</i> , 2005, 84, 250-257.	1.8	57
15	Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. <i>Haematologica</i> , 2005, 90, 1502-10.	3.5	55
16	Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. <i>Cancer Genetics and Cytogenetics</i> , 2005, 157, 53-61.	1.0	44
17	Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells. <i>Haematologica</i> , 2011, 96, 1284-1292.	3.5	44
18	Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients. <i>Annals of Hematology</i> , 2005, 84, 785-791.	1.8	43

#	ARTICLE	IF	CITATIONS
19	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , 2020, 6, 1011.	7.1	39
20	Allotransplantation for Patients Age \leq 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
21	Current status and trends in the diagnostics of AML and MDS. <i>Blood Reviews</i> , 2018, 32, 508-519.	5.7	35
22	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
23	Evaluation of complete disease remission in acute myeloid leukemia. <i>Cancer</i> , 2006, 106, 839-847.	4.1	34
24	Chimerism studies with quantitative real-time PCR in stem cell recipients with Acute myeloid leukemia. <i>Experimental Hematology</i> , 2010, 38, 1261-1271.	0.4	32
25	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404.	7.1	32
26	<i>TET2</i> deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by <i>TET2</i> mutations on the remaining allele. <i>British Journal of Haematology</i> , 2012, 156, 67-75.	2.5	27
27	Minimal Residual Disease Diagnostics and Chimerism in the Post-Transplant Period in Acute Myeloid Leukemia. <i>Scientific World Journal, The</i> , 2011, 11, 310-319.	2.1	24
28	Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders. <i>Cancer Genetics and Cytogenetics</i> , 2005, 160, 179-183.	1.0	23
29	Mutational profiling in patients with MDS: Ready for every-day use in the clinic?. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 32-42.	1.7	23
30	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
31	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
32	Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome. <i>Experimental Hematology</i> , 2020, 88, 7-14.e3.	0.4	21
33	Current status of gene expression profiling in the diagnosis and management of acute leukaemia. <i>British Journal of Haematology</i> , 2009, 145, 555-568.	2.5	20
34	Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1779.	3.7	20
35	Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders. <i>Blood Cancer Journal</i> , 2018, 8, 28.	6.2	19
36	Platelet Transfusion Induces Alloimmunization to D and Non-D Rhesus Antigens. <i>Transfusion Medicine and Hemotherapy</i> , 2018, 45, 167-172.	1.6	19

#	ARTICLE	IF	CITATIONS
37	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
38	MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation. <i>Leukemia Research</i> , 2020, 89, 106296.	0.8	18
39	CAR T-cell therapy and critical care. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1318-1325.	1.9	18
40	Monitoring and Prevention of Relapse after Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S62-S73.	2.0	17
41	Outcomes of rituximab+BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	4.1	17
42	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 971-979.	2.0	16
43	Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 276-281.	2.0	16
44	Autologous Transplantation for Older Adults with AML. <i>Cancers</i> , 2018, 10, 340.	3.7	16
45	Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial. <i>Blood</i> , 2018, 132, 2680-2680.	1.4	16
46	Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma. <i>Blood</i> , 2011, 118, 148-148.	1.4	16
47	<i>In Situ</i> Validation of the Endothelial Cell Receptor GRP78 in a Case of Rhinocerebral Mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	15
48	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	1.2	15
49	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	1.2	15
50	Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients. <i>Cancers</i> , 2021, 13, 6073.	3.7	15
51	Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy. <i>RMD Open</i> , 2022, 8, e002166.	3.8	15
52	Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. <i>Cancers</i> , 2022, 14, 2516.	3.7	15
53	Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. <i>Leukemia Research</i> , 2012, 36, 826-831.	0.8	14
54	Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries. <i>Cancer Epidemiology</i> , 2019, 59, 51-57.	1.9	14

#	ARTICLE	IF	CITATIONS
55	High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 1923-1925.	2.4	14
56	Comparison of outcomes of HCT in blast phase of <i>t(9;22) BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.	5.2	14
57	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
58	Current concepts and future directions for hemato-oncologic diagnostics. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102977.	4.4	14
59	sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma. <i>Current Issues in Molecular Biology</i> , 2022, 44, 1463-1471.	2.4	14
60	Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft. <i>Hematological Oncology</i> , 2018, 36, 436-444.	1.7	13
61	Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 511-514.	1.3	13
62	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1137-1143.	2.0	13
63	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13
64	Enhanced Immune Reconstitution of $\gamma\delta$ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 841-850.	1.2	13
65	Genetic alterations crossing the borders of distinct hematopoietic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 64-79.	4.4	12
66	Reduced survival after autologous stem cell transplantation in myeloma and lymphoma patients with low vitamin D serum levels. <i>Hematological Oncology</i> , 2020, 38, 523-530.	1.7	12
67	Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML. <i>European Journal of Haematology</i> , 2021, 106, 606-615.	2.2	12
68	BM11-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. <i>Cancers</i> , 2021, 13, 581.	3.7	12
69	Pitfalls in the molecular follow up of NPM1 mutant acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, e486-e488.	3.5	11
70	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10.	1.2	11
71	Iron overload is correlated with impaired autologous stem cell mobilization and survival in acute myeloid leukemia. <i>Transfusion</i> , 2018, 58, 2365-2373.	1.6	10
72	Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients. <i>Hematological Oncology</i> , 2018, 36, 671-678.	1.7	10

#	ARTICLE	IF	CITATIONS
73	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	7.0	10
74	Excellent outcome after consolidation with autologous transplantation in patients with core binding factor acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 1690-1693.	2.4	10
75	Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. <i>Swiss Medical Weekly</i> , 2020, 150, w20364.	1.6	10
76	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160.	3.5	10
77	Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expression. <i>Hematological Oncology</i> , 2018, 36, 576-583.	1.7	8
78	Simple acute phase protein score to predict long-term survival in patients with acute myeloid leukemia. <i>Hematological Oncology</i> , 2020, 38, 74-81.	1.7	8
79	Detection of rare reciprocal RUNX1 rearrangements by next-generation sequencing in acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 268-274.	2.8	8
80	Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia. <i>Hematological Oncology</i> , 2020, 38, 425-431.	1.7	8
81	Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial. <i>Bone Marrow Transplantation</i> , 2022, 57, 990-997.	2.4	8
82	Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2005, 46, 357-366.	1.3	7
83	Critical evaluation of current molecular MRD strategies including NGS for the management of AML patients with multiple mutations. <i>Hematological Oncology</i> , 2019, 37, 319-322.	1.7	7
84	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820.	1.3	7
85	Prophylactic corticosteroid use prevents engraftment syndrome in patients after autologous stem cell transplantation. <i>Hematological Oncology</i> , 2021, 39, 97-104.	1.7	7
86	Management of transthyretin amyloidosis. <i>Swiss Medical Weekly</i> , 2021, 151, w30053.	1.6	7
87	What role can next-generation sequencing play in myelodysplastic syndrome care?. <i>Expert Review of Hematology</i> , 2019, 12, 379-382.	2.2	6
88	Improved survival rates of AML patients following admission to the intensive care unit. <i>Leukemia and Lymphoma</i> , 2019, 60, 2423-2431.	1.3	6
89	(2R,3S)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 2842.	3.7	6
90	Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in NPM1 mutant acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e9-e12.	3.5	6

#	ARTICLE	IF	CITATIONS
91	A randomized evaluation of vinorelbine versus gemcitabine chemotherapy mobilization of stem cells in myeloma patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 2047-2051.	2.4	6
92	When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1026.	2.4	6
93	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
94	Diagnostic and Prognostic Implications of Caspase-1 and PD-L1 Co-Expression Patterns in Myelodysplastic Syndromes. <i>Cancers</i> , 2021, 13, 5712.	3.7	6
95	Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre-CAR T cell era. <i>Hematological Oncology</i> , 2022, 40, 292-296.	1.7	6
96	Chimeric antigen receptor T-cell therapy for relapsed mantle cell lymphoma: real-world experience from a single tertiary care center. <i>Bone Marrow Transplantation</i> , 2022, 57, 1010-1012.	2.4	6
97	Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients. <i>HemaSphere</i> , 2019, 3, e180.	2.7	5
98	A case of CIDP concurrent with MGUS IgG kappa responsive to autologous stem cell transplantation. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	5
99	Clonal Hematopoiesis after Autologous Stem Cell Transplantation Does Not Confer Adverse Prognosis in Patients with AML. <i>Cancers</i> , 2021, 13, 3190.	3.7	5
100	Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8092.	4.1	5
101	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	5.2	5
102	Deferasirox (Exjade®) Given During Conditioning Regimen (FLAMSA/Busulfan/ATG) Reduces the Appearance of Labile Plasma Iron in Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 3023-3023.	1.4	5
103	REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021012.	1.3	5
104	Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 224-231.	2.4	5
105	Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML. <i>Cancers</i> , 2022, 14, 1024.	3.7	5
106	Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients. <i>HemaSphere</i> , 2019, 3, e176.	2.7	4
107	Diagnostic, Clinical and Post-SARS-CoV-2 Scenarios in Cancer Patients with SARS-CoV-2: Retrospective Analysis in Three German Cancer Centers. <i>Cancers</i> , 2021, 13, 2917.	3.7	4
108	Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine. <i>Cancers</i> , 2021, 13, 3296.	3.7	4

#	ARTICLE	IF	CITATIONS
109	Multilineage Dysplasia Has No Prognostic Impact in 108 Adult Patients with CEBPA Mutated AML Supporting the WHO Proposal to Classify These Patients As A Molecularly Defined Unique Entity. <i>Blood</i> , 2011, 118, 1443-1443.	1.4	4
110	Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 374.e1-374.e9.	1.2	4
111	Clinical value of molecular MRD monitoring by next-generation sequencing in patients with <i>IDH2</i> mutated AML. <i>Leukemia and Lymphoma</i> , 2019, 60, 2588-2590.	1.3	3
112	Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9562.	2.6	3
113	Post-transplant MFC-MRD status on day +100 predicts outcomes for refractory AML patients.. <i>Transplantation and Cellular Therapy</i> , 2022, , .	1.2	3
114	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	1.2	3
115	Autologous stem cell transfusions on multiple days in patients with multiple myeloma—Does it matter?. <i>Hematological Oncology</i> , 2019, 37, 649-651.	1.7	2
116	Experiences with next-generation sequencing in relapsed acute myeloid leukemia: a patient case series. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020068.	1.3	2
117	Induction Chemotherapy Followed Immediately by Busulfan-Based Reduced Conditioning and Allografting in Elderly Patients with Advanced MDS or sAML. <i>Blood</i> , 2009, 114, 3387-3387.	1.4	2
118	Ganglioneuroblastoma infiltrating the bone marrow in an adult. <i>British Journal of Haematology</i> , 2011, 153, 544-544.	2.5	1
119	Systemic mastocytosis with an associated hematological neoplasms: One or two entities?. <i>EJHaem</i> , 2020, 1, 353-355.	1.0	1
120	Conditioning Intensity in Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2011, 118, 501-501.	1.4	1
121	Novel Adaptive T-Cell Oncological Treatments Lead to New Challenges for Medical Emergency Teams: A 2-Year Experience From a Tertiary-Care Hospital in Switzerland. , 2021, 3, e0552.		1
122	Related Vs Unrelated Donors After Auto-Allo Tandem Stem Cell Transplantation for Newly Diagnosed Patients with Multiple Myeloma.. <i>Blood</i> , 2009, 114, 1201-1201.	1.4	1
123	Patients with Therapy-Related Myeloid Disorders Share Genetic Features but Can Be Separated by Blast Counts and Cytogenetic Risk Groups Into Prognostically Relevant Subgroups.. <i>Blood</i> , 2011, 118, 3583-3583.	1.4	1
124	Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology. <i>Current Oncology</i> , 2022, 29, 766-776.	2.2	1
125	BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL—A Pilot Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3748.	2.4	1
126	Coincidence of 5q deletion and the <i>JAK2</i> V617F mutation: report of two patients with overlapping myelodysplastic and myeloproliferative features and review of the literature. <i>Leukemia and Lymphoma</i> , 2018, 59, 2233-2237.	1.3	0

#	ARTICLE	IF	CITATIONS
127	Oral and Subcutaneous Anticancer Therapy Training Course for Non-physician Healthcare Professionals: a Survey Evaluating the Relevance of its Content and its Implications in the Practice of Cancer Care. <i>Journal of Cancer Education</i> , 2022, 37, 120-127.	1.3	0
128	Risk stratification systems for allogeneic haematopoietic stem-cell transplantation. <i>Lancet Haematology</i> , 2021, 8, e166-e167.	4.6	0
129	Rituximab Plus Donor Lymphocyte Infusion (DLI) to Prevent or Treat Relapse for B Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT). <i>Blood</i> , 2008, 112, 4304-4304.	1.4	0
130	EZH2 Mutations Can Be Detected in 23% of t(10;11)(p13;q14)/PICALM-MLLT10 Positive Acute Leukemias. <i>Blood</i> , 2011, 118, 3440-3440.	1.4	0
131	Measurement of Liver Iron Concentration by Quantum Interference Device Biosusceptometry (SQUID) Validates Serum Ferritin As Prognostic Parameter for Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 1018-1018.	1.4	0
132	Prognosis of MDS Subtypes RARS, RCMD and RCMD-RS Does Not Differ by Cytomorphologic Criteria but Cytogenetics Allows to Delineate a Subgroup with Inferior Clinical Course. <i>Blood</i> , 2011, 118, 3796-3796.	1.4	0
133	Bone Marrow Cellularity, but Not Dysplasia, Is An Additional Prognostic Factor for Patients with Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 4467-4467.	1.4	0
134	Donor Choice for Allogeneic Stem Cell Transplantation for AML – A Retrospective Single Centre Long-Term Analysis. <i>Blood</i> , 2011, 118, 4147-4147.	1.4	0
135	Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients. <i>Blood</i> , 2011, 118, 3024-3024.	1.4	0
136	Molecular Profile and Cytomorphological Manifestation of Isolated Y Loss in Myelodysplastic Syndromes. <i>Blood</i> , 2018, 132, 4358-4358.	1.4	0
137	How to Collect the Minimum-Targeted CD3+ Cells for CAR-T Therapy- the Bern Approach. <i>Blood</i> , 2019, 134, 2457-2457.	1.4	0
138	A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients. <i>Blood</i> , 2019, 134, 1963-1963.	1.4	0
139	Rebound Thrombocytosis after Induction Chemotherapy Is a Strong Biomarker for Favorable Outcome in AML Patients. <i>Blood</i> , 2019, 134, 5101-5101.	1.4	0
140	Autologous Stem Cell Transfusions on Multiple Days in Patients with Multiple Myeloma - Does It Matter?. <i>Blood</i> , 2019, 134, 3252-3252.	1.4	0
141	Correlation between the Degree of Bone Marrow Involvement and the Results of NGS in Plasma Cell Neoplasms. <i>Blood</i> , 2020, 136, 9-10.	1.4	0
142	High-Dose Chemotherapy with Bendamustin and Melphalan Improves the Rate of Complete Remission in Myeloma Patients in First Remission Compared to Standard Melphalan Alone. <i>Blood</i> , 2020, 136, 39-40.	1.4	0